| JPMORGAN stuft AIR FRANCE-KLM auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Air France-KLM auf "Overweight" mit einem Kursziel von 16 Euro belassen. Letzte Indikationen der Fluggesellschaft vor dem anstehenden... ► Artikel lesen |
| JPMORGAN stuft AIR FRANCE-KLM auf 'Positiv' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Air France-KLM von 15 auf 16 Euro angehoben und die Einstufung auf "Overweight" belassen. Analyst Harry Gowers drückte den Papieren... ► Artikel lesen |
| BERNSTEIN RESEARCH stuft AIR FRANCE-KLM auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Air France-KLM mit einem Kursziel von 10,20 Euro auf "Market-Perform" belassen. Nachdem Easyjet der Übernahmeofferte von Castlelake... ► Artikel lesen |
| Koninklijke Vopak N.V.: Vopak completes acquisition of majority stake in Green Energy Storage (GES) and takes final investment decision on 200 MW/ 800 MWh battery storage project in the Netherlands | Vopak completes acquisition of majority stake in Green Energy Storage (GES) and takes final investment decision on 200 MW/ 800 MWh battery storage project in the NetherlandsRotterdam / Breda, the... ► Artikel lesen |
| Koninklijke Vopak N.V.: Conditional Investment Decision taken for extension of EemsEnergyTerminal | Conditional Investment Decision taken for extension of EemsEnergyTerminalRotterdam, the Netherlands, 1 June 2026The conditional Final Investment Decision (cFID) marks a major milestone in the continuation... ► Artikel lesen |
| Koninklijke Vopak N.V.: Vopak reaches agreement with Green Energy Storage (GES) for majority stake in GES to accelerate large-scale battery storage in the Netherlands | Vopak reaches agreement with Green Energy Storage (GES) for majority stake in GES to accelerate large-scale battery storage in the NetherlandsRotterdam / Breda, the Netherlands - 7 May 2026Royal Vopak... ► Artikel lesen |
| Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen |
| Pharming Group N.V.: Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York | Leiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New... ► Artikel lesen |
| Pharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of Shareholders | Leiden, the Netherlands, May 28, 2026: Pharming Group ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at... ► Artikel lesen |